focus -WSS

focus

author：entertainment 2025-08-24 04:09:24 - browse：57241

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Former medical device CEO who sold dummy, plastic parts convicted of fraud

knowledge

WSS

Pharma patents targeted by Biden in move to slash drug prices

Chemotherapy shortages won’t get better under Biden’s latest plan

Pregnancy discrimination could be enabled by AI

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Leukemia patients are helped by Syndax's new type of therapy

Novo Nordisk obesity pill bests Wegovy in early trial

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

How to save PrEP access — and even expand it

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Affirmative action in medical school literally saved lives

Change Healthcare cyberattack prompts Medicare loan program

Continuity nursing helped my family in our darkest PICU moments

Change Healthcare payments predicted restored March 15

Medicare proposal to cover medical devices draws a mixed reaction

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Drug repurposing or repositioning? The language matters

What causes an itch? Researchers may have solved the mystery

hotspot

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

SCOTUS to consider access to abortion pill mifepristone

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Patients' immediate access to test results puts radiologists in a bind

Radiology is caught between AI's potential and concern for patients

Headspace, Meta partner to launch VR meditation app for Quest

focus

hotspot

knowledge

entertainment